Trypanocidal Activity of Aziridinyl Nitrobenzamide Prodrugs (cid:1)

The trypanocidal agents nifurtimox and benznidazole both function as prodrugs and must undergo enzyme- mediated activation, a reaction catalyzed by type I nitroreductase (NTR). In the search for new parasitic therapies, we have utilized this finding to investigate whether aziridinyl nitrobenzamide derivatives have activity against bloodstream-form Trypanosoma brucei and Trypanosoma cruzi amastigotes, parasite stages that replicate in the mammalian host. For T. cruzi drug screening, we generated trypanosomes that expressed the luciferase reporter gene and optimized a mammalian infection model in a 96-well plate format. A subset of compounds having a 5-(aziridin-1-yl)-2,4-dinitrobenzyl structure was shown to be metabolized by purified T. brucei NTR and when screened against both parasite life cycle stages displayed significant growth-inhibitory properties: the most potent compounds generated 50% inhibitory concentrations of <1 (cid:1) M. The trypanocidal activity was shown to be NTR specific, since

[1]  C. Bern,et al.  Chagas disease in Spain, the United States and other non-endemic countries. , 2010, Acta tropica.

[2]  Michelle R. Arkin,et al.  Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.

[3]  K. Read,et al.  Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African Trypanosomiasis , 2010, Antimicrobial Agents and Chemotherapy.

[4]  W. Denny,et al.  A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors , 2010, Cancer Chemotherapy and Pharmacology.

[5]  B. Hall,et al.  Exploiting the Drug-Activating Properties of a Novel Trypanosomal Nitroreductase , 2009, Antimicrobial Agents and Chemotherapy.

[6]  S. Montgomery,et al.  An estimate of the burden of Chagas disease in the United States. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Salah Ghabri,et al.  Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial , 2009, The Lancet.

[8]  N. James,et al.  A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  M. Bosenberg,et al.  Nifurtimox Induces Apoptosis of Neuroblastoma Cells In Vitro and In Vivo , 2009, Journal of pediatric hematology/oncology.

[10]  Longqin Hu,et al.  Design of anticancer prodrugs for reductive activation , 2009, Medicinal research reviews.

[11]  J. Samuelson,et al.  Giardia, Entamoeba, and Trichomonas Enzymes Activate Metronidazole (Nitroreductases) and Inactivate Metronidazole (Nitroimidazole Reductases) , 2008, Antimicrobial Agents and Chemotherapy.

[12]  D. Horn,et al.  A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes , 2008, Proceedings of the National Academy of Sciences.

[13]  J. Boucher,et al.  Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases. , 2008, Chemical research in toxicology.

[14]  G. Priotto,et al.  Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  F. Checchi,et al.  Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series , 2007, PLoS neglected tropical diseases.

[16]  S. White,et al.  Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. , 2007, Journal of molecular biology.

[17]  J. Wastling,et al.  A Novel Giardia lamblia Nitroreductase, GlNR1, Interacts with Nitazoxanide and Other Thiazolides , 2007, Antimicrobial Agents and Chemotherapy.

[18]  M. Zacks Impairment of cell division of Trypanosoma cruzi epimastigotes. , 2007, Memorias do Instituto Oswaldo Cruz.

[19]  J. Jannin,et al.  The future of Chagas disease control. , 2006, Trends in parasitology.

[20]  F. Checchi,et al.  Three Drug Combinations for Late-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in Uganda , 2006, PLoS clinical trials.

[21]  K. McCarten,et al.  Antitumor Activity of Nifurtimox Observed in a Patient With Neuroblastoma , 2006, Journal of pediatric hematology/oncology.

[22]  M. Taylor,et al.  pTcINDEX: a stable tetracycline-regulated expression vector for Trypanosoma cruzi , 2006, BMC biotechnology.

[23]  W. Wilson,et al.  Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. , 2005, Toxicology.

[24]  D. Horn,et al.  Tagging a T. brucei RRNA locus improves stable transfection efficiency and circumvents inducible expression position effects. , 2005, Molecular and biochemical parasitology.

[25]  W. Denny,et al.  Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase. , 2004, Journal of medicinal chemistry.

[26]  W. Wilson,et al.  2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT , 2004, British Journal of Cancer.

[27]  Michael P Barrett,et al.  The trypanosomiases , 2003, The Lancet.

[28]  W. Denny,et al.  Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy) , 2003, Journal of biomedicine & biotechnology.

[29]  W. Denny,et al.  Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. , 2003, Chemical research in toxicology.

[30]  Hilary G. Morrison,et al.  Evidence for Lateral Transfer of Genes Encoding Ferredoxins, Nitroreductases, NADH Oxidase, and Alcohol Dehydrogenase 3 from Anaerobic Prokaryotes to Giardialamblia and Entamoebahistolytica , 2002, Eukaryotic Cell.

[31]  D. Warhurst,et al.  In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. , 2002, The Journal of antimicrobial chemotherapy.

[32]  S. D. de Castro,et al.  A critical review on Chagas disease chemotherapy. , 2002, Memorias do Instituto Oswaldo Cruz.

[33]  D. Kerr,et al.  Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  T. C. Jenkins,et al.  Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. , 2000, Cancer research.

[35]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.

[36]  R. Gazzinelli,et al.  Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. , 1998, Molecular and biochemical parasitology.

[37]  R. D. Conti,et al.  Application of a multi-endpoint cytotoxicity assay to the trypanocidal compounds 2-propen-1-amine derivatives and determination of their acute toxicity , 1998 .

[38]  A. Jaiswal,et al.  Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. , 1997, Archives of biochemistry and biophysics.

[39]  S. Martínez-Calvillo,et al.  pRIBOTEX expression vector: a pTEX derivative for a rapid selection of Trypanosoma cruzi transfectants. , 1997, Gene.

[40]  L. Amzel,et al.  Molecular Basis of the Catalytic Differences among DT-diaphorase of Human, Rat, and Mouse* , 1997, The Journal of Biological Chemistry.

[41]  F. Buckner,et al.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase , 1996, Antimicrobial agents and chemotherapy.

[42]  P. Biggs,et al.  Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. , 1993, Biochemical pharmacology.

[43]  F. Friedlos,et al.  The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. , 1992, Biochemical pharmacology.

[44]  M. Miles,et al.  A shuttle vector which facilitates the expression of transfected genes in Trypanosoma cruzi and Leishmania. , 1992, Nucleic acids research.

[45]  F. Friedlos,et al.  Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. , 1991, Biochemical pharmacology.

[46]  M. Miles,et al.  Trypanosoma cruzi glycosomal glyceraldehyde‐3‐phosphate dehydrogenase does not conform to the ‘hotspot’ topogenic signal model. , 1990, The EMBO journal.

[47]  H Hirumi,et al.  Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. , 1989, The Journal of parasitology.

[48]  U. Graf,et al.  Genotoxicity testing of antiparasitic nitrofurans in the Drosophila wing somatic mutation and recombination test. , 1989, Mutagenesis.

[49]  L. Filardi,et al.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[50]  L. C. Ferreira,et al.  Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. , 1986, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[51]  R. Mason,et al.  Reduction of nifurtimox and nitrofurantoin to free radical metabolites by rat liver mitochondria. Evidence of an outer membrane-located nitroreductase. , 1984, The Journal of biological chemistry.

[52]  R. Mason,et al.  Generation of free radicals induced by nifurtimox in mammalian tissues. , 1981, The Journal of biological chemistry.

[53]  R. Mason,et al.  Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. , 1979, The Journal of biological chemistry.

[54]  E. Grunberg,et al.  Chemotherapeutic properties of heterocyclic compounds: monocyclic compounds with five-membered rings. , 1973, Annual review of microbiology.